Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Advocate Medical Group Neurology
Melvin Wichter is a Neurologist practicing medicine in Palos Heights, Illinois. Dr. Wichter is rated as an Advanced provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Parkinson's Disease, Epilepsy, and Memory Loss. Dr. Wichter is board certified in American Board Of Psychiatry & Neurology.
Friedemann Paul practices practicing medicine in Goyang, Republic of Korea. Paul is rated as an Elite expert by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. They are also highly rated in 40 other conditions, according to our data. Their clinical expertise encompasses Multiple Sclerosis (MS), Transverse Myelitis, Optic Neuritis, and Neuromyelitis Optica.
MN - Neuro MS
Sean Pittock is a Neurologist practicing medicine in Rochester, Minnesota. Dr. Pittock is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Transverse Myelitis, Optic Neuritis, Neuromyelitis Optica, and Encephalitis.
Summary: The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), ...
Summary: The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to deve...